Altasciences and Certara Form Strategic Partnership to Advance Model-Informed Drug Development Altasciences and Certara have announced a strategic partnership aimed at accelerating early-stage drug development through the integration of model-informed drug development technologies, biosimulation tools, and fully integrated research services.…
Aptar Pharma Advances FDA-Supported Research on Next-Generation Propellants for Metered-Dose Inhalers Aptar Pharma, a global company specializing in drug delivery systems, dosing technologies, protection solutions, and pharmaceutical services, has announced continued progress in its multi-year research collaboration with the U.S.…
Viridian Therapeutics Plans Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Shares, and Series B Non-Voting Convertible Preferred Stock Viridian Therapeutics (Nasdaq: VRDN), a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune and rare diseases, has…
VectorBuilder Granted European Patent for MiniVec™, a Plasmid Backbone Enhancing Safety and Scalable Manufacturing in Genetic Medicine VectorBuilder, a global provider of gene delivery technologies and contract development and manufacturing (CDMO) services, has announced a significant advancement in its innovation…
Merck Finalizes Acquisition of Terns Pharmaceuticals, Strengthening Its Portfolio Merck & Co.—known as MSD outside the United States and Canada—has officially completed its acquisition of Terns Pharmaceuticals, marking a significant expansion of its oncology pipeline and reinforcing its long-term strategy…
Alnylam Pharmaceuticals to Showcase New Analyses at Heart Failure 2026 Highlighting the Consistent Clinical Profile of Vutrisiran in ATTR-CM Alnylam Pharmaceuticals (Nasdaq: ALNY) has announced that it will present a comprehensive set of new data analyses for vutrisiran in patients…
Armatus Unveils Scalable Potency Assay Platform to Advance Next-Generation Gene Silencing Therapies Armatus Bio, a late-preclinical biotechnology company focused on developing vectorized RNA interference (RNAi) therapies for neuromuscular disorders, has announced the publication of new research in Molecular Therapy Advances…
Takeda Pharmaceutical Company Reports Positive Topline Results from Pivotal Phase 2/3 Study of TAK-881 in Primary Immunodeficiency Disease Takeda Pharmaceutical Company (TSE:4502/NYSE:TAK) has reported positive topline results from its pivotal Phase 2/3 clinical trial, TAK-881-3001, evaluating an investigational immunoglobulin therapy…
Satellite Bio Secures U.S. Food and Drug Administration Rare Pediatric Disease Designation for SB-101 in Urea Cycle Disorders Satellite Biosciences has announced a significant regulatory milestone, revealing that the U.S. Food and Drug Administration has granted Rare Pediatric Disease (RPD)…
UCB Expands Immunology Pipeline with Planned Acquisition of Candid Therapeutics and Its Novel T-Cell Engager Platform UCB has taken a significant step forward in its strategic expansion within immunology by entering into a definitive agreement to acquire Candid Therapeutics, a…
Incyte Secures FDA Approval for Jakafi XR™ (ruxolitinib) Extended-Release Tablets Across Multiple Hematologic Indications Incyte has announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets, introducing a new once-daily treatment option for patients…
Knoa Pharma Launches as Public Health-Focused Company Aiming to Support Patients and Combat the Opioid Crisis Knoa Pharma LLC has officially launched as a newly established independent organization with a mission centered on improving public health, ensuring responsible access to…